IL-17 regulates the expression of major histocompatibility complex II and VEGF in DLBCL mice on tumor growth

Abstract

Objective: To investigate the effect of interleukin-17 (IL-17) on vascular endothelial growth factor (VEGF) and major histocompatibility complex II (MHC II) expression in diffuse large B-cell lymphoma (DLBCL) and the relationship thereof with tumor development.

Methods: CD4 + CD62L + naïve cells from spleen of BALB/c mice were purified by the immunomagnetic beads method. T-cells were cultured in vitro with anti-CD3, anti-CD28, transforming growth factor-β (TGF-β), and interleukin-6 (IL-6). The human germinal center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL) cell line SUDHL-4 was cultured and inoculated into severe combined immune deficiency (SCID) mice to establish a DLBCL mice model. Tumor-bearing mice were inoculated with Th17 cells. DLBCL was detected by ELISA. The expression of IL-17, VEGF, and MHC II were detected by immunohistochemistry (IH).

Results: After Th17 cells were inoculated, the IL-17 expression level was higher than that of the control group, the VEGF expression level as lower than that of the control group, and the MHC II expression level was higher than that of the control group. There was a significant negative correlation between IL-17 and VEGF, and there was a significant positive correlation between IL-17 and MHC II.

Conclusion: The VEGF and MHC II expression levels can be used as an index to judge the DLBCL disease status. IL-17 can produce negative regulation of VEGF and positive regulation of MHC II, thereby affecting the DLBCL disease process. Detection of IL-17, VEGF, and MHC II expression levels have value in judging the DLBCL disease status and progression.

Keywords: Diffuse large B cell lymphoma, Th17, interleukin 17, vascular endothelial growth factor, major histocompatibility complex II